Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04188548
Title	A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Acronym	EMBER
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Eli Lilly and Company
Indications	Her2-receptor negative breast cancer endometrial cancer Her2-receptor positive breast cancer
Therapies	Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP \| BEL \| AUS